How Trelagliptin treats blood sugar

Trelagliptin (Trelagliptin) is an orally active dipeptidyl peptidase (DPP)-4 inhibitor, developed by Takeda and approved in Japan for the treatment of type 2 diabetes (T2DM). Unlike other approved drugs in the same class, which are usually administered once daily, trotagliptin can be administered once a week. Phase II development of troagliptin was halted in the United States and the European Union because the costs associated with obtaining approval in those markets were deemed to be too high.

By inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), troagliptin inactivates glucagon-like peptide-1 (GLP-1), which is stimulated to be secreted into the blood after oral administration. Trelagliptin can increase the blood concentration of GLP-1 and promote pancreatic insulin secretion according to glucose concentration. Trelagliptin is a substrate of P-glycoprotein, and in vitro studies have shown mild inhibition of P-glycoprotein transport or inhibition of uptake of metformin, an organic cation transporter-2 (OCT2) substrate.

The original drug of trotagliptin has not yet received relevant approval for marketing in China, so it cannot be covered by medical insurance. Currently, the price of trotagliptin original drug, specification 50mg*20 tablets per box, which is currently on the market overseas, may be around RMB 1,000 (the price may fluctuate due to exchange rates). There are also generic Trelagliptin drugs produced in other countries, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 100mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan per box (the price may fluctuate due to exchange rates). For more drug information and specific prices, please consult Yaode Medical Consultant.